KLK3 and TMPRSS2 for molecular lymph-node staging in prostate cancer patients undergoing radical prostatectomy

被引:10
|
作者
Lunger, Lukas [1 ]
Retz, Margitta [1 ]
Bandur, Miriam [1 ]
Souchay, Marc [1 ]
Vitzthum, Elisabeth [1 ]
Jaeger, Marion [1 ]
Weirich, Gregor [2 ]
Schuster, Tibor [3 ]
Autenrieth, Michael [1 ]
Kuebler, Hubert [1 ,4 ]
Maurer, Tobias [1 ,5 ,6 ]
Thalgott, Mark [1 ]
Herkommer, Kathleen [1 ]
Koll, Florestan [1 ]
Gschwend, Juergen E. [1 ]
Nawroth, Roman [1 ]
Heck, Matthias M. [1 ]
机构
[1] Tech Univ Munich, Rechts Isar Med Ctr, Dept Urol, Munich, Germany
[2] Tech Univ Munich, Rechts Isar Med Ctr, Dept Pathol & Pathol Anat, Munich, Germany
[3] McGill Univ, Dept Family Med, Montreal, PQ, Canada
[4] Univ Wurzburg, Dept Urol, Wurzburg, Germany
[5] Univ Hosp Hamburg Eppendorf, Dept Urol, Hamburg, Germany
[6] Univ Hosp Hamburg Eppendorf, Martini Klin Prostate Canc Ctr, Hamburg, Germany
关键词
METASTASES; SURVIVAL; IMPACT; MICROMETASTASES; THERAPY; MARKER; PCR;
D O I
10.1038/s41391-020-00283-3
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Lymph-node (LN) metastasis in prostate cancer (PC) is a main risk factor for tumor recurrence after radical prostatectomy (RP). Molecular analysis facilitates detection of small-volume LN metastases with higher sensitivity than histopathology. We aimed to prospectively evaluate six candidate gene markers for detection of pelvic LN metastases and to determine their ability to predict biochemical recurrence-free survival (bRFS) in patients treated with RP. Methods The expression of kallikrein 2, 3, and 4 (KLK2, KLK3, and KLK4), prostate-specific membrane antigen (PSMA), transmembrane serine protease 2 (TMPRSS2) and transient receptor potential cation channel subfamily M member 8 (TRPM8) was assessed using qPCR. We analyzed LNs from 111 patients (intermediate PC,n = 32 (29%); high-risk PC,n = 79 (71%)) who underwent RP and extended pelvic lymph-node dissection without neoadjuvant treatment. Results Overall, 2411 LNs were examined by molecular and histopathologic examination. Histopathology detected 69 LN metastases in 28 (25%) patients. KLK2 and KLK3 diagnostically performed best and classified all pN1-patients correctly as molecular node-positive (molN1/pN1). The concordance on LN level was best for KLK3 (96%). KLK2, KLK3, KLK4, PSMA, TMPRSS2, and TRPM8 reclassified 27 (24%), 32 (29%), 29 (26%), 8 (7%), 13 (12%), and 23 (21%) pN0-patients, respectively, as node-positive (pN0/molN1). On multivariable cox regression analysis molecular LN status (molN1 vs. molN0) using KLK3 (HR 4.0,p = 0.04) and TMPRSS2 (HR 5.1,p = 0.02) were independent predictors of bRFS. Median bRFS was shorter in patients with only molecular positive LNs (molN1/pN0) for KLK3 (24 months,p = 0.001) and for TMPRSS2 (12 months,p < 0.001) compared to patients with negative nodes (molN0/pN0) (median bRFS not reached). Conclusions For diagnostic purposes, KLK3 showed highest concordance with histopathology for detection of LN metastases in PC patients undergoing RP. For prognostic purposes, KLK3 and TMPRSS2 expression were superior to histopathologic LN status and other transcripts tested for molecular LN status. We suggest a combined KLK3/TMPRSS2 panel as a valuable diagnostic and prognostic tool for molecular LN analysis.
引用
收藏
页码:362 / 369
页数:8
相关论文
共 50 条
  • [21] Benefit of a more extended pelvic lymph node dissection among patients undergoing radical prostatectomy for localized prostate cancer: A causal mediation analysis
    Wettstein, Marian S.
    David, Luke A.
    Pazhepurackel, Clinsy
    Qureshi, Aatif A.
    Zisman, Alex
    Nesbitt, Michael
    Saba, Karim
    Herrera-Caceres, Jaime O.
    Fankhauser, Christian D.
    Ahmad, Ardalan
    Hamilton, Robert J.
    Eberli, Daniel
    Zlotta, Alexandre R.
    Sulser, Tullio
    Fleshner, Neil E.
    Poyet, Cedric
    Finelli, Antonio
    Hermanns, Thomas
    Kulkarni, Girish S.
    PROSTATE, 2021, 81 (05) : 286 - 294
  • [22] Eliminating microscopic lymph node metastasis by performing pelvic lymph node dissection during radical prostatectomy for prostate cancer
    Furubayashi, Nobuki
    Negishi, Takahito
    Uozumi, Tomoharu
    Shiraishi, Kouichi
    Taguchi, Kenichi
    Shimokawa, Mototsugu
    Nakamura, Motonobu
    MOLECULAR AND CLINICAL ONCOLOGY, 2020, 12 (02) : 104 - 110
  • [23] Identifying the Candidates Who Will Benefit From Extended Pelvic Lymph Node Dissection at Radical Prostatectomy Among Patients With Prostate Cancer
    Yang, Guanjie
    Xie, Jun
    Guo, Yadong
    Yuan, Jing
    Wang, Ruiliang
    Guo, Changcheng
    Peng, Bo
    Yao, Xudong
    Yang, Bin
    FRONTIERS IN ONCOLOGY, 2022, 11
  • [24] Complete Tissue Submission to Increase Lymph Node Detection in Pelvic Lymph Node Packets Submitted for Patients Undergoing Radical Prostatectomy and Radical Cystectomy
    Rais-Bahrami, Soroush
    Tracht, Jessica P.
    McIntosh, Eleanor R.
    Lai, Win Shun
    Gordetsky, Jennifer B.
    INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY, 2017, 25 (01) : 12 - 17
  • [25] Metastatic lymph nodes outside the extended lymphadenectomy template correlate with advanced staging but not grading in prostate cancer patients undergoing radical prostatectomy
    Karwacki, Jakub
    Mioskowska, Agnieszka
    Tomecka, Paulina
    Maczka, Krystian
    Gurwin, Adam
    Kobylanski, Maximilian
    Halon, Agnieszka
    Szuba, Przemyslaw
    Zdrojowy, Romuald
    Szydelko, Tomasz
    Malkiewicz, Bartosz
    INTERNATIONAL UROLOGY AND NEPHROLOGY, 2025,
  • [26] Extent of lymph node dissection improves survival in prostate cancer patients treated with radical prostatectomy without lymph node invasion
    Preisser, Felix
    Bandini, Marco
    Marchioni, Michele
    Nazzani, Sebastiano
    Tian, Zhe
    Pompe, Raisa S.
    Fossati, Nicola
    Briganti, Alberto
    Saad, Fred
    Shariat, Shahrokh F.
    Heinzer, Hans
    Huland, Hartwig
    Graefen, Markus
    Tilki, Derya
    Karakiewicz, Pierre I.
    PROSTATE, 2018, 78 (06) : 469 - 475
  • [27] Natural History of Clinical Recurrence Patterns of Lymph Node-Positive Prostate Cancer After Radical Prostatectomy
    Moschini, Marco
    Sharma, Vidit
    Zattoni, Fabio
    Quevedo, J. Fernando
    Davis, Brian J.
    Kwona, Eugene
    Karnes, R. Jeffrey
    EUROPEAN UROLOGY, 2016, 69 (01) : 135 - 142
  • [28] Long-term outcome after radical prostatectomy for patients with lymph node positive prostate cancer in the prostate specific antigen era
    Boorjian, Stephen A.
    Thompson, R. Houston
    Siddiqui, Sameer
    Bagniewski, Stephanie
    Bergstralh, Erik J.
    Karnes, R. Jeffrey
    Frank, Igor
    Blute, Michael L.
    JOURNAL OF UROLOGY, 2007, 178 (03) : 864 - 870
  • [29] Management of Patients with Node-positive Prostate Cancer at Radical Prostatectomy and Pelvic Lymph Node Dissection: A Systematic Review
    Marra, Giancarlo
    Valerio, Massimo
    Heidegger, Isabel
    Tsaur, Igor
    Mathieu, Romain
    Ceci, Francesco
    Ploussard, Guillaume
    van den Bergh, Roderick C. N.
    Kretschmer, Alexander
    Thibault, Constance
    Ost, Piet
    Tilki, Derya
    Kasivisvanathan, Veeru
    Moschini, Marco
    Sanchez-Salas, Rafael
    Gontero, Paolo
    Karnes, R. Jeffrey
    Montorsi, Francesco
    Gandaglia, Giorgio
    EUROPEAN UROLOGY ONCOLOGY, 2020, 3 (05): : 565 - 581
  • [30] The significance of pelvic lymph node dissection in radical prostatectomy and its influence on the prognosis of patients with prostate cancer
    Shen, Xianqi
    Li, Jialun
    Zhou, Zenghui
    Zhang, Wenhui
    Ji, Jin
    Qu, Min
    Wang, Yan
    Gao, Xu
    TRANSLATIONAL ANDROLOGY AND UROLOGY, 2024, 13 (09) : 2070 - 2078